Efficacy and Safety of Camrelizumab in Real-World Study

Sponsor
Guangdong Association of Clinical Trials
Study ID
NCT04631146
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.

Key Dates

Start date
Nov 30, 2020
Status verified
Oct 2020
Primary completion
Jun 30, 2021
Completion
Dec 30, 2021

Study Design

Enrollment
450 participants (estimated)

Arms

  • Arm: Camrelizumab-treated advanced NSCLC
    Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.

Primary Outcome Measure

pCR [ Time Frame: From August 1, 2019 to June 31, 2021 ]

Central Contacts

Related Studies